Applied DNA Sciences, Inc. (APDN)
USD 0.89
(-2.09%)
USD 0.89
(-2.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.95 Million USD | 21.59% |
| 2022 | -13.96 Million USD | -13.65% |
| 2021 | -12.29 Million USD | 1.94% |
| 2020 | -12.53 Million USD | -37.38% |
| 2019 | -9.12 Million USD | 21.66% |
| 2018 | -11.64 Million USD | 9.16% |
| 2017 | -12.82 Million USD | -5.08% |
| 2016 | -12.19 Million USD | -55.33% |
| 2015 | -7.85 Million USD | 36.0% |
| 2014 | -12.27 Million USD | -20.59% |
| 2013 | -10.17 Million USD | -56.37% |
| 2012 | -6.5 Million USD | 19.22% |
| 2011 | -8.05 Million USD | -13.2% |
| 2010 | -7.11 Million USD | -3.2% |
| 2009 | -6.89 Million USD | -65.95% |
| 2008 | -4.15 Million USD | 66.86% |
| 2007 | -12.54 Million USD | 20.15% |
| 2006 | -15.7 Million USD | 64.03% |
| 2005 | -43.65 Million USD | -148.29% |
| 2004 | -17.58 Million USD | -406.96% |
| 2003 | -3.46 Million USD | -40314.39% |
| 2002 | -8582.00 USD | -50.03% |
| 2001 | -5720.00 USD | -70.54% |
| 2000 | -3354.00 USD | -112.01% |
| 1999 | -1582.00 USD | -149.53% |
| 1998 | -634.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.61 Million USD | 4.52% |
| 2024 Q1 | -3.78 Million USD | 9.15% |
| 2024 Q3 | -3.34 Million USD | 7.49% |
| 2023 Q1 | 1.41 Million USD | 132.47% |
| 2023 FY | -10.95 Million USD | 21.59% |
| 2023 Q3 | -2.85 Million USD | -5.74% |
| 2023 Q2 | -2.7 Million USD | -290.58% |
| 2023 Q4 | -4.17 Million USD | -45.88% |
| 2022 Q2 | -1.99 Million USD | 56.95% |
| 2022 Q3 | -2.83 Million USD | -42.29% |
| 2022 Q1 | -4.63 Million USD | -3.95% |
| 2022 FY | -13.96 Million USD | -13.65% |
| 2022 Q4 | -4.36 Million USD | -53.98% |
| 2021 FY | -12.29 Million USD | 1.94% |
| 2021 Q1 | -2.97 Million USD | 26.64% |
| 2021 Q2 | -2.31 Million USD | 22.1% |
| 2021 Q3 | -3.36 Million USD | -45.4% |
| 2021 Q4 | -4.45 Million USD | -32.36% |
| 2020 Q2 | -2.68 Million USD | -2.71% |
| 2020 Q1 | -2.61 Million USD | -40.11% |
| 2020 FY | -12.53 Million USD | -37.38% |
| 2020 Q4 | -4.05 Million USD | -27.09% |
| 2020 Q3 | -3.18 Million USD | -18.89% |
| 2019 FY | -9.12 Million USD | 21.66% |
| 2019 Q3 | -1.43 Million USD | 45.62% |
| 2019 Q4 | -1.86 Million USD | -30.19% |
| 2019 Q1 | -3.19 Million USD | 7.77% |
| 2019 Q2 | -2.63 Million USD | 17.63% |
| 2018 Q2 | -2.13 Million USD | 32.59% |
| 2018 Q3 | -2.86 Million USD | -33.95% |
| 2018 Q4 | -3.46 Million USD | -20.9% |
| 2018 Q1 | -3.17 Million USD | -11.67% |
| 2018 FY | -11.64 Million USD | 9.16% |
| 2017 Q4 | -2.84 Million USD | -9.24% |
| 2017 FY | -12.82 Million USD | -5.08% |
| 2017 Q3 | -2.6 Million USD | 23.95% |
| 2017 Q2 | -3.42 Million USD | 13.45% |
| 2017 Q1 | -3.95 Million USD | -64.05% |
| 2016 Q1 | -2.92 Million USD | -498.57% |
| 2016 FY | -12.19 Million USD | -55.33% |
| 2016 Q2 | -3.44 Million USD | -18.03% |
| 2016 Q3 | -3.42 Million USD | 0.72% |
| 2016 Q4 | -2.4 Million USD | 29.59% |
| 2015 Q3 | -1.67 Million USD | 11.0% |
| 2015 Q4 | -487.91 Thousand USD | 70.82% |
| 2015 FY | -7.85 Million USD | 36.0% |
| 2015 Q2 | -1.87 Million USD | 50.78% |
| 2015 Q1 | -3.81 Million USD | -34.3% |
| 2014 Q4 | -2.84 Million USD | -14.3% |
| 2014 FY | -12.27 Million USD | -20.59% |
| 2014 Q1 | -3.81 Million USD | -62.08% |
| 2014 Q2 | -3.12 Million USD | 17.98% |
| 2014 Q3 | -2.48 Million USD | 20.47% |
| 2013 FY | -10.17 Million USD | -56.37% |
| 2013 Q1 | -2.37 Million USD | -34.25% |
| 2013 Q2 | -2.6 Million USD | -9.95% |
| 2013 Q4 | -2.35 Million USD | 17.27% |
| 2013 Q3 | -2.84 Million USD | -9.01% |
| 2012 FY | -6.5 Million USD | 19.22% |
| 2012 Q4 | -1.76 Million USD | -23.81% |
| 2012 Q3 | -1.42 Million USD | 4.92% |
| 2012 Q2 | -1.5 Million USD | 17.18% |
| 2012 Q1 | -1.81 Million USD | 52.01% |
| 2011 Q3 | -1.49 Million USD | 10.39% |
| 2011 Q4 | -3.77 Million USD | -153.32% |
| 2011 FY | -8.05 Million USD | -13.2% |
| 2011 Q1 | -1.12 Million USD | 39.54% |
| 2011 Q2 | -1.66 Million USD | -47.9% |
| 2010 FY | -7.11 Million USD | -3.2% |
| 2010 Q1 | -1.58 Million USD | -32.65% |
| 2010 Q2 | -1.2 Million USD | 24.05% |
| 2010 Q4 | -1.86 Million USD | 24.69% |
| 2010 Q3 | -2.47 Million USD | -105.43% |
| 2009 Q2 | -1.77 Million USD | 37.38% |
| 2009 Q1 | -2.83 Million USD | -248.7% |
| 2009 Q4 | -1.19 Million USD | -8.95% |
| 2009 FY | -6.89 Million USD | -65.95% |
| 2009 Q3 | -1.09 Million USD | 38.24% |
| 2008 Q4 | -812.36 Thousand USD | 7.58% |
| 2008 Q3 | -878.99 Thousand USD | 0.0% |
| 2008 Q2 | -878.99 Thousand USD | 49.69% |
| 2008 Q1 | -1.74 Million USD | 71.41% |
| 2008 FY | -4.15 Million USD | 66.86% |
| 2007 FY | -12.54 Million USD | 20.15% |
| 2007 Q4 | -6.11 Million USD | -190.61% |
| 2007 Q3 | -2.1 Million USD | 1.6% |
| 2007 Q2 | -2.13 Million USD | 2.5% |
| 2007 Q1 | -2.19 Million USD | 77.31% |
| 2006 Q1 | -2.43 Million USD | 88.42% |
| 2006 Q4 | -9.65 Million USD | -533.46% |
| 2006 Q3 | -1.52 Million USD | -6.86% |
| 2006 Q2 | -1.42 Million USD | 41.48% |
| 2006 FY | -15.7 Million USD | 64.03% |
| 2005 Q3 | -2.75 Million USD | 55.31% |
| 2005 Q1 | -10.79 Million USD | -63.78% |
| 2005 Q2 | -6.15 Million USD | 42.98% |
| 2005 FY | -43.65 Million USD | -148.29% |
| 2005 Q4 | -21.05 Million USD | -665.31% |
| 2004 Q2 | -1.9 Million USD | 74.22% |
| 2004 Q1 | -7.4 Million USD | -68.7% |
| 2004 Q3 | -1.67 Million USD | 12.4% |
| 2004 Q4 | -6.59 Million USD | -294.12% |
| 2004 FY | -17.58 Million USD | -406.96% |
| 2003 Q1 | -147.19 Thousand USD | 0.0% |
| 2003 Q3 | -325.88 Thousand USD | 24.74% |
| 2003 Q4 | -4.39 Million USD | -1247.5% |
| 2003 FY | -3.46 Million USD | -40314.39% |
| 2003 Q2 | -432.98 Thousand USD | -194.16% |
| 2002 Q1 | -210.00 USD | 97.43% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 100.0% |
| 2002 FY | -8582.00 USD | -50.03% |
| 2001 Q3 | -105.00 USD | 0.0% |
| 2001 Q1 | -5159.00 USD | -2766.11% |
| 2001 FY | -5720.00 USD | -70.54% |
| 2001 Q4 | -8162.00 USD | -7673.33% |
| 2001 Q2 | -105.00 USD | 97.96% |
| 2000 Q4 | -180.00 USD | -13.21% |
| 2000 FY | -3354.00 USD | -112.01% |
| 2000 Q2 | -222.00 USD | 92.69% |
| 2000 Q3 | -159.00 USD | 28.38% |
| 2000 Q1 | -3037.00 USD | 0.0% |
| 1999 Q2 | -159.00 USD | 0.0% |
| 1999 Q3 | -158.00 USD | 0.63% |
| 1999 Q4 | - USD | 100.0% |
| 1999 FY | -1582.00 USD | -149.53% |
| 1998 FY | -634.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 88.749% |
| Biodesix, Inc. | -41.34 Million USD | 73.506% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -37.376% |
| Castle Biosciences, Inc. | -67.97 Million USD | 83.887% |
| DarioHealth Corp. | -56.18 Million USD | 80.506% |
| Exact Sciences Corporation | -215.01 Million USD | 94.906% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.998% |
| Illumina, Inc. | -1.06 Billion USD | 98.975% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -6.517% |
| iSpecimen Inc. | -11.16 Million USD | 1.934% |
| Standard BioTools Inc. | -76.6 Million USD | 85.701% |
| 23andMe Holding Co. | -321.35 Million USD | 96.592% |
| Medpace Holdings, Inc. | 336.82 Million USD | 103.252% |
| NeoGenomics, Inc. | -107.73 Million USD | 89.833% |
| Inotiv, Inc. | -81.46 Million USD | 86.554% |
| Psychemedics Corporation | -2.92 Million USD | -274.984% |
| Prenetics Global Limited | -52.51 Million USD | 79.142% |
| Precipio, Inc. | -7.62 Million USD | -43.744% |
| RadNet, Inc. | 98.69 Million USD | 111.098% |
| Sotera Health Company | 276.69 Million USD | 103.959% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -152.032% |
| Exagen Inc. | -22.83 Million USD | 52.037% |
| Natera, Inc. | -446.24 Million USD | 97.545% |
| Aspira Women's Health Inc. | -18.85 Million USD | 41.899% |
| Neogen Corporation | 58.66 Million USD | 118.672% |
| Myriad Genetics, Inc. | -123.7 Million USD | 91.145% |
| ICON Public Limited Company | 956.15 Million USD | 101.146% |
| Bionano Genomics, Inc. | -215.24 Million USD | 94.911% |
| CareDx, Inc | -101.9 Million USD | 89.251% |
| Check-Cap Ltd. | -19.28 Million USD | 43.209% |
| Twist Bioscience Corporation | -220.83 Million USD | 95.04% |
| Guardant Health, Inc. | -564.72 Million USD | 98.06% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -322.322% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 84.933% |
| Sera Prognostics, Inc. | -39.82 Million USD | 72.494% |
| OPKO Health, Inc. | -157.02 Million USD | 93.024% |
| Personalis, Inc. | -109.93 Million USD | 90.037% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -152.032% |
| MDxHealth SA | -27.32 Million USD | 59.918% |
| Prenetics Global Limited | -52.51 Million USD | 79.142% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -4.111% |
| Mainz Biomed B.V. | -26.64 Million USD | 58.891% |
| Trinity Biotech plc | -27.04 Million USD | 59.5% |
| Neuronetics, Inc. | -30.55 Million USD | 64.151% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -37.376% |